Combined Diazoxide and Metformin Therapy in Children With Hypothalamic Obesity Secondary to Craniopharyngioma: A Pilot Study
46 children under the age of 22 years have been treated surgically for craniopharyngioma
tumor and are currently followed at the Hospital for Sick Children, Toronto. Approximately
50% are obese (BMI ≥ 95th percentile for age and gender assessed from the updated Centre for
Disease Control growth charts), all of whom have panhypopituitarism requiring hormone
replacement therapy. These children are assessed regularly in Endocrine Clinic and also are
invited to attend a comprehensive care clinic for evaluation by an endocrinologist
(Principal Investigator), neurosurgical clinical nurse practitioner, dietitian, exercise
physiologist, psychologist and social worker to provide multi-disciplinary dietary and
exercise consultation and psychological counseling for weight related concerns. This clinic
will provide the infrastructure for recruitment and follow-up of study patients.
Recruitment of eight subjects for this pilot study will occur over 6 months from patients
attending the comprehensive clinic. This number was chosen as it is equivalent to the
number chosen in the pilot study of octreotide by Lustig which showed beneficial changes in
body mass index with treatment.
This study evaluates a novel combination therapy in children with hypothalamic obesity at
very high risk for complications. Evaluation of insulin resistance and metabolic changes on
therapy will allow a better understanding of how insulin secretion relates to weight gain in
this population. Successful therapy in a pilot setting will provide necessary data for a
larger randomized trial in individuals with hypothalamic obesity including children with
craniopharyngioma and others with damage to the hypothalamus secondary to other tumors,
surgery or cranial irradiation.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Change in BMI and BMI SDS (calculated using for Disease Control formula - www.cdc.gov.doc) over 6 months of treatment compared to change in BMI and BMI SDS over 6 month 'run-in' period (prior to study start)
6 months prior to baseline, Baseline, 6 months after baseline
No
Jill Hamilton, MD
Principal Investigator
The Hospital for Sick Children
Canada: Health Canada
1000008879
NCT00892073
May 2006
January 2008
Name | Location |
---|